CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 6 enrolled
Drug / intervention
Dexmedetomidinedrug
Likely dose
Dexmedetomidine 1 mcg/Kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01721460
NCT01721460Phase 4Completed
CompareCT.gov

Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation Surgery

University of Wisconsin, Madison·interventional·Posted Nov 5, 2012·Updated Dec 8, 2017

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine for Parkinson's Disease and Deep Brain Stimulation Surgery. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this research study is to find out whether dexmedetomidine changes brain cell activity in the subthalamic nucleus (STN).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease, Deep Brain Stimulation Surgery
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 5, 2012
Enrollment StartNov 1, 2012
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.7 years ago

Interventions

Dexmedetomidinedrug

Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.